Wells Kenneth B, Schoenbaum Michael, Duan Naihua, Miranda Jeanne, Tang Lingqi, Sherbourne Cathy
RAND Corporation, Santa Monica, CA 90407-2138, USA.
Psychiatr Serv. 2007 Oct;58(10):1269-78. doi: 10.1176/ps.2007.58.10.1269.
This study explored the cost-effectiveness of quality-improvement interventions for depression in primary care, relative to usual care, among patients with subthreshold depression or depressive disorder.
A total of 746 primary care patients in managed care organizations with 12-month depressive disorder and 502 with current depressive symptoms but no disorder (subthreshold depression) participated in a group-level randomized controlled trial initiated between June 1996 and March 1997. Matched clinics were randomly assigned to enhanced usual care or one of two quality improvement interventions that provided education to manage depression over time and resources to facilitate access to medication management or psychotherapy for six to 12 months.
The cost-effectiveness ratio for the pooled intervention groups versus usual care was $2,028 for patients with subthreshold depression (95% confidence interval [CI]=-$17,225 to $21,282) and $53,716 for those with depressive disorder (CI=$14,194 to $93,238), by using a measure of quality-adjusted life years (QALY) based on the 12-Item Short Form Health Survey. Similar results were obtained when alternative QALY measures were used.
Although precision was limited, even the upper limit of the 95% CIs suggests that such interventions are as cost-effective for patients with subthreshold depression as are many widely used medical therapies. Despite lack of evidence for efficacy of treatments for subthreshold depression, disease management programs that support clinical care decisions over time for patients with subthreshold depression or depressive disorder can yield cost-effectiveness ratios comparable to those of widely adopted medical therapies. Achieving greater certainty about average cost-effectiveness would require a much larger study.
本研究探讨了在初级保健中,相对于常规护理,针对亚阈值抑郁症或抑郁症患者的抑郁症质量改进干预措施的成本效益。
共有746名管理式医疗组织中患有12个月抑郁症的初级保健患者以及502名有当前抑郁症状但无疾病(亚阈值抑郁症)的患者参与了一项于1996年6月至1997年3月启动的组级随机对照试验。匹配的诊所被随机分配到强化常规护理组或两种质量改进干预措施之一,这两种干预措施会随着时间推移提供管理抑郁症的教育,并提供资源以促进获得药物管理或心理治疗,为期6至12个月。
使用基于12项简短健康调查问卷的质量调整生命年(QALY)衡量标准,亚阈值抑郁症患者的合并干预组与常规护理组的成本效益比为2028美元(95%置信区间[CI]= -17225美元至21282美元),抑郁症患者为53716美元(CI = 14194美元至93238美元)。使用替代QALY衡量标准时也获得了类似结果。
尽管精确度有限,但即使95%置信区间的上限也表明,此类干预措施对于亚阈值抑郁症患者的成本效益与许多广泛使用的药物治疗相当。尽管缺乏亚阈值抑郁症治疗疗效的证据,但随着时间推移为亚阈值抑郁症或抑郁症患者支持临床护理决策的疾病管理项目可以产生与广泛采用的药物治疗相当的成本效益比。要更确定平均成本效益,需要进行规模大得多的研究。